267 related articles for article (PubMed ID: 36306107)
1. Epigenomic and transcriptomic landscaping unraveled candidate repositioned therapeutics for non-functioning pituitary neuroendocrine tumors.
Aydin B; Beklen H; Arga KY; Bayrakli F; Turanli B
J Endocrinol Invest; 2023 Apr; 46(4):727-747. PubMed ID: 36306107
[TBL] [Abstract][Full Text] [Related]
2. Past, Present, and Future of Therapies for Pituitary Neuroendocrine Tumors: Need for Omics and Drug Repositioning Guidance.
Aydin B; Yildirim E; Erdogan O; Arga KY; Yilmaz BK; Bozkurt SU; Bayrakli F; Turanli B
OMICS; 2022 Mar; 26(3):115-129. PubMed ID: 35172108
[TBL] [Abstract][Full Text] [Related]
3. Transcriptomic analysis identifies a tumor subtype mRNA classifier for invasive non-functioning pituitary neuroendocrine tumor diagnostics.
Bao X; Wang G; Yu S; Sun J; He L; Zhao H; Ma Y; Wang F; Wang X; Wang R; Yu J
Theranostics; 2021; 11(1):132-146. PubMed ID: 33391466
[No Abstract] [Full Text] [Related]
4. Quantitative Acetylomics Revealed Acetylation-Mediated Molecular Pathway Network Changes in Human Nonfunctional Pituitary Neuroendocrine Tumors.
Wen S; Li J; Yang J; Li B; Li N; Zhan X
Front Endocrinol (Lausanne); 2021; 12():753606. PubMed ID: 34712204
[TBL] [Abstract][Full Text] [Related]
5. Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.
Herrgott GA; Asmaro KP; Wells M; Sabedot TS; Malta TM; Mosella MS; Nelson K; Scarpace L; Barnholtz-Sloan JS; Sloan AE; Selman WR; deCarvalho AC; Poisson LM; Mukherjee A; Robin AM; Lee IY; Snyder J; Walbert T; Rosenblum M; Mikkelsen T; Bhan A; Craig J; Kalkanis S; Rock J; Noushmehr H; Castro AV
Neuro Oncol; 2022 Jul; 24(7):1126-1139. PubMed ID: 35212383
[TBL] [Abstract][Full Text] [Related]
6. Annotation of pituitary neuroendocrine tumors with genome-wide expression analysis.
Tebani A; Jotanovic J; Hekmati N; Sivertsson Å; Gudjonsson O; Edén Engström B; Wikström J; Uhlèn M; Casar-Borota O; Pontén F
Acta Neuropathol Commun; 2021 Nov; 9(1):181. PubMed ID: 34758873
[TBL] [Abstract][Full Text] [Related]
7. Clinical presentation and recurrence of pituitary neuroendocrine tumors: results from a single referral center in Colombia.
Jimenez-Canizales CE; Rojas W; Alonso D; Romero I; Tabares S; Veronesi Zuluaga LA; Modica R; Colao A
J Endocrinol Invest; 2023 Nov; 46(11):2275-2286. PubMed ID: 37002436
[TBL] [Abstract][Full Text] [Related]
8. Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients.
Guaraldi F; Morandi L; Zoli M; Mazzatenta D; Righi A; Evangelisti S; Ambrosi F; Tonon C; Giannini C; Lloyd RV; Asioli S
Clin Endocrinol (Oxf); 2022 Dec; 97(6):763-772. PubMed ID: 36161330
[TBL] [Abstract][Full Text] [Related]
9. Pangenomic Classification of Pituitary Neuroendocrine Tumors.
Neou M; Villa C; Armignacco R; Jouinot A; Raffin-Sanson ML; Septier A; Letourneur F; Diry S; Diedisheim M; Izac B; Gaspar C; Perlemoine K; Verjus V; Bernier M; Boulin A; Emile JF; Bertagna X; Jaffrezic F; Laloe D; Baussart B; Bertherat J; Gaillard S; Assié G
Cancer Cell; 2020 Jan; 37(1):123-134.e5. PubMed ID: 31883967
[TBL] [Abstract][Full Text] [Related]
10. Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
Taghavi SF; Ghorbani M; Panahi M; Nazem S; Karimi M; Salimi V; Tavakoli-Yaraki M
Mol Biol Rep; 2023 Aug; 50(8):6425-6434. PubMed ID: 37326745
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of epithelial-mesenchymal transition and medical treatment related-genes in non-functioning pituitary neuroendocrine tumors.
Gil J; Marques-Pamies M; Valassi E; Serra G; Salinas I; Xifra G; Casano-Sancho P; Carrato C; Biagetti B; Sesmilo G; Marcos-Ruiz J; Rodriguez-Lloveras H; Rueda-Pujol A; Aulinas A; Blanco A; Hostalot C; Simó-Servat A; Muñoz F; Rico M; Ibáñez-Domínguez J; Cordero E; Webb SM; Jordà M; Puig-Domingo M
Front Endocrinol (Lausanne); 2023; 14():1129213. PubMed ID: 37033229
[TBL] [Abstract][Full Text] [Related]
12. Identification of the enhancer RNAs related to tumorgenesis of pituitary neuroendocrine tumors.
Wang L; Wei C; Wang Y; Huang N; Zhang T; Dai Y; Xue L; Lin S; Wu ZB
Front Endocrinol (Lausanne); 2023; 14():1149997. PubMed ID: 37534217
[TBL] [Abstract][Full Text] [Related]
13. Identification of biomarkers associated with the invasion of nonfunctional pituitary neuroendocrine tumors based on the immune microenvironment.
Wu J; Guo J; Fang Q; Liu Y; Li C; Xie W; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1131693. PubMed ID: 37522128
[TBL] [Abstract][Full Text] [Related]
14. Identification of cholesterol metabolism-related subtypes in nonfunctioning pituitary neuroendocrine tumors and analysis of immune infiltration.
Feng T; Hou P; Mu S; Fang Y; Li X; Li Z; Wang D; Chen L; Lu L; Lin K; Wang S
Lipids Health Dis; 2023 Aug; 22(1):127. PubMed ID: 37563740
[TBL] [Abstract][Full Text] [Related]
15. Differential Expression of HMGA1 and HMGA2 in pituitary neuroendocrine tumors.
Portovedo S; Gaido N; de Almeida Nunes B; Nascimento AG; Rocha A; Magalhães M; Nascimento GC; Pires de Carvalho D; Soares P; Takiya C; Faria MDS; Miranda-Alves L
Mol Cell Endocrinol; 2019 Jun; 490():80-87. PubMed ID: 30999005
[TBL] [Abstract][Full Text] [Related]
16. From Pituitary Adenoma to Pituitary Neuroendocrine Tumors: How Molecular Pathways may Impact the Therapeutic Management?
Chiloiro S; De Marinis L
Endocr Metab Immune Disord Drug Targets; 2021; 21(10):1744-1759. PubMed ID: 34425741
[TBL] [Abstract][Full Text] [Related]
17. Single-cell transcriptome and genome analyses of pituitary neuroendocrine tumors.
Cui Y; Li C; Jiang Z; Zhang S; Li Q; Liu X; Zhou Y; Li R; Wei L; Li L; Zhang Q; Wen L; Tang F; Zhou D
Neuro Oncol; 2021 Nov; 23(11):1859-1871. PubMed ID: 33908609
[TBL] [Abstract][Full Text] [Related]
18. Pituitary Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior.
Spada A; Mantovani G; Lania AG; Treppiedi D; Mangili F; Catalano R; Carosi G; Sala E; Peverelli E
Neuroendocrinology; 2022; 112(1):15-33. PubMed ID: 33524974
[TBL] [Abstract][Full Text] [Related]
19. SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth
Wang X; Fang Y; Zhou Y; Guo X; Xu K; Li C; Zhang J; Hong Y
Front Endocrinol (Lausanne); 2020; 11():566761. PubMed ID: 33362712
[TBL] [Abstract][Full Text] [Related]
20. Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies.
Aydin B; Caliskan A; Arga KY
EPMA J; 2021 Sep; 12(3):383-401. PubMed ID: 34567287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
